Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of PA-111 in healthy subjects.
Eligibility
Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
Exclusion Criteria:
* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
* Other exclusions applied
Primary outcome measure(s)
Maximum concentration of drug in plasma (Cmax) — pre-dose (0hour) to 72hours Cmax of PA-111
Area under the plasma concentration-time curve during dosing interval (AUCt) — pre-dose (0hour) to 72hours AUCt of PA-111
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.